Literature DB >> 34993032

Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy.

Andee L Fontenot1, Weldon J Furr1, Ammar Husan1, Muhammad W Khan1.   

Abstract

Palmar-plantar erythrodysesthesia (PPE), more commonly known as hand-foot syndrome, is a dermatologic complication following chemotherapy with selective agents. In this article, we present the case of a young lady with stage III breast cancer who developed palmar-plantar erythrodysesthesia following treatment with Herceptin (trastuzumab), an unusual complication of this particular drug. From our review of literature, this is the second known occurrence of PPE secondary to trastuzumab monotherapy.
Copyright © 2021, Fontenot et al.

Entities:  

Keywords:  dermatologic complication; dermatology; erythema; hand foot syndrome; herceptin; oncology; palmar plantar erythrodysesthesia; trastuzumab

Year:  2021        PMID： 34993032      PMCID： PMC8720033          DOI： 10.7759/cureus.20060

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  16 in total

1.  Trastuzumab-related palmar plantar erythrodysaesthesia.

Authors:  L M Tho; N Bose; L Robertson; S Bhattacharya; L McClue; L Anderson; E Fraser; K Graham; H Yosef; G Lumsden
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-10-22       Impact factor: 4.126

2.  Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.

Authors:  ZhengGang Ren; KangShun Zhu; HaiYan Kang; MinQiang Lu; ZengQiang Qu; LiGong Lu; TianQiang Song; WeiPing Zhou; Hui Wang; WeiZhu Yang; Xuan Wang; YongPing Yang; LeHua Shi; YuXian Bai; XiaoFeng Guo; Sheng-Long Ye
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.

Authors:  Yoon-Koo Kang; Sung Sook Lee; Dok Hyun Yoon; So Young Lee; Young Ju Chun; Min Sun Kim; Min-Hee Ryu; Heung-Moon Chang; Jae-Lyun Lee; Tae Won Kim
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

Review 4.  The hand-foot-syndrome associated with medical tumor therapy - classification and management.

Authors:  Annette Degen; Mareike Alter; Florian Schenck; Imke Satzger; Bernward Völker; Alexander Kapp; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2010-05-06       Impact factor: 5.584

Review 5.  Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.

Authors:  Joan D Webster-Gandy; Chris How; Karen Harrold
Journal:  Eur J Oncol Nurs       Date:  2007-03-09       Impact factor: 2.398

6.  Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.

Authors:  Gunter von Minckwitz; Mahdi Rezai; Sibylle Loibl; Peter A Fasching; Jens Huober; Hans Tesch; Ingo Bauerfeind; Jörn Hilfrich; Holger Eidtmann; Bernd Gerber; Claus Hanusch; Thorsten Kühn; Andreas du Bois; Jens-Uwe Blohmer; Christoph Thomssen; Serban Dan Costa; Christian Jackisch; Manfred Kaufmann; Keyur Mehta; Michael Untch
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

Review 7.  Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Authors:  Adam D Lipworth; Caroline Robert; Andrew X Zhu
Journal:  Oncology       Date:  2009-11-16       Impact factor: 2.935

8.  Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

Authors:  Roger von Moos; Beat J K Thuerlimann; Matti Aapro; Daniel Rayson; Karen Harrold; Jalid Sehouli; Florian Scotte; Domenica Lorusso; Reinhard Dummer; Mario E Lacouture; Jürgen Lademann; Axel Hauschild
Journal:  Eur J Cancer       Date:  2008-03-10       Impact factor: 9.162

Review 9.  Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Authors:  Mario E Lacouture; Shenhong Wu; Caroline Robert; Michael B Atkins; Heidi H Kong; Joan Guitart; Claus Garbe; Axel Hauschild; Igor Puzanov; Doru T Alexandrescu; Roger T Anderson; Laura Wood; Janice P Dutcher
Journal:  Oncologist       Date:  2008-09-08

10.  Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Authors:  Julien Autier; Bernard Escudier; Janine Wechsler; Alain Spatz; Caroline Robert
Journal:  Arch Dermatol       Date:  2008-07
View more
  1 in total

1.  Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database.

Authors:  Yu Yoshida; Sayaka Sasaoka; Mizuki Tanaka; Kiyoka Matsumoto; Misaki Inoue; Riko Satake; Kazuyo Shimada; Ririka Mukai; Takaaki Suzuki; Mari Iwata; Fumiya Goto; Takayuki Mori; Koki Mori; Tomoaki Yoshimura; Mitsuhiro Nakamura
Journal:  Ther Adv Drug Saf       Date:  2022-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.